innovation,alternative_names,category,technology,disease,indication,country,archetype,trial_status,date_trial_status,nra,nra_date,nra_body,nra_note,gra,gra_date,gra_body,gra_note,eml,eml_date,eml_country,eml_note,prob_success,procurement,reg_approval,policy_readiness,social_context,guidelines,policy_implemented,date_market,country_supply,distribution,delivery_model,efficacy,dalys,disease_prevalence,improvement,dalys_averted,deaths_averted,yll,hs_costs,dalys_monetized,time_to_regulatory_approval,time_approval_to_first_launch,time_launch_to_20lmic,expected_date_of_regulatory_approval,expected_date_of_first_launch,expected_date_of_market,readiness,financing
MalariaSense AI RDT Reader,MalariaSense; MS-Reader; RDT-AI Scan,Diagnostic,AI/algorithmic,Malaria,Rapid interpretation of malaria RDTs for uncomplicated febrile illness in outpatient primary care,Kenya,Platform enhancer,Implementation/Pilot,15-03-2025,Yes,20-11-2024,PPB,Approved as SaMD for use with WHO-prequalified RDTs,Yes,10/1/25,WHO PQ,PQDx listing as accessory diagnostic software,No,,Kenya,Diagnostics not explicitly listed on EML,0.68,Government tender,NRA+GRA,High,Low barrier,Available (limited),Partial,1/7/25,Partial,Facility-based,Hybrid,0.92,3200000,18000,Improved diagnostic accuracy and reduced false negatives,42000,2100,38000,-1500000,42000000,3.5,0.5,2,12/1/24,6/1/25,6/1/27,78,2
TB-LATENT XR,TB-LATENT XR; Rifapentine-XR,Therapeutics,Long-acting formulation,Tuberculosis,Once-monthly preventive therapy for latent TB infection in adults,South Africa,Long-acting simplifier,Phase 2,10/1/25,No,,,Not yet submitted,No,,,Unknown,No,,South Africa,Not listed; preventive regimens under review,0.45,Donor-funded,None,Medium,Moderate barrier,In development,No,1/1/29,No,Central medical stores,Facility outpatient,0.75,14500000,22000,Improved adherence through reduced dosing frequency,68000,5400,61000,8200000,68000000,6,1,3.5,1/1/28,1/1/29,7/1/32,42,1
SafeBirth PPH Patch,SafeBirth Patch; OxytocinPatch,Medical Device,Drug-device combination,MNCH,Prevention of postpartum hemorrhage during facility-based vaginal delivery in LMIC hospitals,Senegal,Delivery optimizer,Phase 3,20-02-2025,Yes,15-08-2025,SAHPRA,Conditional approval for obstetric use,Yes,1/12/25,WHO PQ,PQ listing for maternal health commodities,Yes,1/6/26,Senegal,Listed under essential obstetric medicines,0.72,Pooled procurement,EML listed,High,Low barrier,Available (widely),Yes,1/9/26,Yes,Hybrid,Inpatient,0.85,8900000,31000,Faster uterotonic delivery and reduced administration errors,120000,9500,110000,4500000,120000000,4.5,0.5,1.5,9/1/25,3/1/26,9/1/27,85,2